# Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia

> **NCT07659938** · NA · NOT_YET_RECRUITING · sponsor: **BioSignal Solutions LLC** · enrollment: 30 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective

## Interventions

- **DEVICE:** Frontal gamma coherence neurofeedback
- **DEVICE:** Placebo Neurofeedback

## Key facts

- **NCT ID:** NCT07659938
- **Lead sponsor:** BioSignal Solutions LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-04
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07659938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07659938, "Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07659938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*